MannKind (MNKD) Stock Forecast & Price Target

Compare

1,869 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MNKD Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

MannKind

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MNKD Stock 12 Month Forecast

Average Price Target

$8.80

▲(115.69%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for MannKind in the last 3 months. The average price target is $8.80 with a high forecast of $11.00 and a low forecast of $7.00. The average price target represents a 115.69% change from the last price of $4.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","7":"$7","12":"$12","4.5":"$4.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,4.150769230769231,4.7215384615384615,5.292307692307693,5.863076923076923,6.433846153846154,7.004615384615385,7.575384615384616,8.146153846153847,8.716923076923077,9.287692307692307,9.858461538461539,10.42923076923077,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,3.9815384615384617,4.383076923076923,4.7846153846153845,5.186153846153847,5.587692307692308,5.989230769230769,6.390769230769231,6.792307692307693,7.193846153846154,7.595384615384615,7.9969230769230775,8.39846153846154,{"y":8.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,3.8430769230769233,4.1061538461538465,4.36923076923077,4.632307692307693,4.895384615384616,5.158461538461538,5.421538461538462,5.684615384615385,5.947692307692308,6.210769230769231,6.473846153846154,6.736923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.67,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$11.00

Average Price Target$8.80

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-1.96%

Downside

Reiterated

07/23/25

MannKind's strong financial performance and optimistic earnings call are somewhat offset by technical analysis signals and high valuation. The company's revenue growth and strategic partnerships are promising, but its balance sheet risks and valuation concerns limit the overall score.

Douglas MiehmRBC Capital

RBC Capital

Buy

96.08%

Upside

Reiterated

07/23/25

RBC Capital Reaffirms Their Buy Rating on MannKind (MNKD)

Brandon FolkesH.C. Wainwright

H.C. Wainwright

Buy

120.59%

Upside

Initiated

07/16/25

MannKind assumed with a Buy at H.C. WainwrightMannKind assumed with a Buy at H.C. Wainwright

Yun ZhongWedbush

Wedbush

$11

Buy

169.61%

Upside

Reiterated

06/27/25

MannKind's Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment

Faisal KhurshidLeerink Partners

Leerink Partners

$9→$7

Buy

71.57%

Upside

Reiterated

06/20/25

MannKind's Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid

Tiago FauthWells Fargo

Wells Fargo

$13→$9

Buy

120.59%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Humana (NYSE: HUM) and MannKind (NASDAQ: MNKD)

Anthony PetroneMizuho Securities

Mizuho Securities

$12

Buy

194.12%

Upside

Initiated

04/09/25

MannKind initiated with an Outperform at MizuhoMannKind initiated with an Outperform at Mizuho

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

Buy

120.59%

Upside

Reiterated

03/20/25

MannKind (MNKD) Gets a Buy from Cantor Fitzgerald

Andreas ArgyridesOppenheimer

Oppenheimer

$12

Buy

194.12%

Upside

Reiterated

11/12/24

Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-1.96%

Downside

Reiterated

07/23/25

Douglas MiehmRBC Capital

RBC Capital

Buy

96.08%

Upside

Reiterated

07/23/25

RBC Capital Reaffirms Their Buy Rating on MannKind (MNKD)

Brandon FolkesH.C. Wainwright

H.C. Wainwright

Buy

120.59%

Upside

Initiated

07/16/25

MannKind assumed with a Buy at H.C. WainwrightMannKind assumed with a Buy at H.C. Wainwright

Yun ZhongWedbush

Wedbush

$11

Buy

169.61%

Upside

Reiterated

06/27/25

MannKind's Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment

Faisal KhurshidLeerink Partners

Leerink Partners

$9→$7

Buy

71.57%

Upside

Reiterated

06/20/25

MannKind's Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid

Tiago FauthWells Fargo

Wells Fargo

$13→$9

Buy

120.59%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Humana (NYSE: HUM) and MannKind (NASDAQ: MNKD)

Anthony PetroneMizuho Securities

Mizuho Securities

$12

Buy

194.12%

Upside

Initiated

04/09/25

MannKind initiated with an Outperform at MizuhoMannKind initiated with an Outperform at Mizuho

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

Buy

120.59%

Upside

Reiterated

03/20/25

MannKind (MNKD) Gets a Buy from Cantor Fitzgerald

Andreas ArgyridesOppenheimer

Oppenheimer

$12

Buy

194.12%

Upside

Reiterated

11/12/24

Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MannKind

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+2.42%

initiated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +2.42% per trade.

3 Months

xxx

Success Rate

5/9 ratings generated profit

Average Return

+14.23%

initiated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +14.23% per trade.

1 Year

Andreas ArgyridesOppenheimer

Success Rate

3/5 ratings generated profit

Average Return

+25.48%

reiterated a buy rating 9 months ago

Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +25.48% per trade.

2 Years

xxx

Success Rate

6/9 ratings generated profit

Average Return

+64.01%

initiated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +64.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNKD Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MNKD has received 13 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. MNKD average Analyst price target in the past 3 months is 8.80.

Each month's total comprises the sum of three months' worth of ratings.

MNKD Financial Forecast

MNKD Earnings Forecast

Next quarter’s earnings estimate for MNKD is $0.05 with a range of $0.04 to $0.07. The previous quarter’s EPS was $0.04. MNKD beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.99% of the time in the same period. In the last calendar year MNKD has Outperformed its overall industry.

MNKD Sales Forecast

Next quarter’s sales forecast for MNKD is $78.74M with a range of $74.90M to $81.50M. The previous quarter’s sales results were $78.35M. MNKD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year MNKD has Outperformed its overall industry.

MNKD Stock Forecast FAQ

What is MNKD’s average 12-month price target, according to analysts?

Based on analyst ratings, MannKind Corporation’s 12-month average price target is 8.80.

What is MNKD’s upside potential, based on the analysts’ average price target?

MannKind Corporation has 115.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MNKD a Buy, Sell or Hold?

MannKind Corporation has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is MannKind Corporation’s price target?

The average price target for MannKind Corporation is 8.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $7.00. The average price target represents 115.69% Increase from the current price of $4.08.

What do analysts say about MannKind Corporation?

MannKind Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of MNKD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

MannKind (MNKD) Stock Forecast & Price Target

MNKD Analyst Ratings

MNKD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MannKind

MNKD Analyst Recommendation Trends

MNKD Financial Forecast

MNKD Earnings Forecast

MNKD Sales Forecast

MNKD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts